Emergent BioSolutions Inc. (EBS)
NYSE: EBSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EBS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $259.65M
- Forward P/E
- 4.83
- EPS (TTM)
- -$5.00
- Dividend yield
- None
- 52-week range
- 4.36 – 14.06
- Day range
- 4.98 – 5.24
- Volume / Avg
- 1.39M / 1.11M
- Beta
- —
- Shares outstanding
- 51.42M
52-week range
EBS stock today
On Nov 20, EBS ended the session at $5.05, shedding $0.10 (1.94%), versus the S&P 500's 3.70% decline. At this level, EBS sits near the bottom of its 52-week range of $4.36 to $14.06: 64.1% below the high, set on Jan 7, 2026 and 15.8% above the low. EBS is down 59.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.7%.
Emergent BioSolutions has posted a net loss over the last twelve months (EPS of -$5.00), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Emergent BioSolutions
Company profileEmergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
- Headquarters
- Gaithersburg, MD
- Employees
- 900
- IPO year
- 2006
- Website
- emergentbiosolutions.com
Financial highlights
Full financialsIn fiscal 2025, Emergent BioSolutions generated $742.9 million in revenue, down 28.8% from fiscal 2024, its first annual decline since 2024. Net income was $52.6 million, for a net margin of 7.1% versus a median of -18.3% in the prior 5 years. Gross margin was 56.1% (up from 34.7%) and operating margin 13.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $742.90M | $1.04B | $1.05B | $1.12B | $1.77B |
| Growth | -28.81% | -0.54% | -6.10% | -36.99% | +12.45% |
| Net income | $52.60M | $-190.60M | $-760.50M | $-211.60M | $219.50M |
| EPS (diluted) | $0.93 | $-3.60 | $-14.85 | $-4.22 | $4.06 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$10.00+98.02%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 1
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $1.06 vs $-0.45
- Surprise
- +335.56%
EBS news
All EBS news- Emergent BioSolutions: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Emergent BioSolutions (EBS) Q3 2026 Earnings Call TranscriptNasdaq
- Emergent Biosolutions Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026Business Wire
Emergent BioSolutions peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALTAltimmune Inc. | 1.33 | -5.67% | $258.80M | vs EBS |
| PRLDPrelude Therapeutics Incorporated | 3.23 | -0.77% | $258.63M | vs EBS |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs EBS |
| QTTBQ32 Bio Inc. | 8.34 | -1.65% | $249.57M | vs EBS |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs EBS |
| TTRXTurn Therapeutics Inc. | 8.10 | -6.31% | $247.49M | vs EBS |
| LFCRLifecore Biomedical Inc. | 6.39 | +0.31% | $242.22M | vs EBS |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs EBS |
Indexes, lists and sector
Emergent BioSolutions stock FAQ
What is Emergent BioSolutions's stock price today?
EBS last traded at $5.05 as of Nov 20, 4:00 PM EST, down 1.94% on the day. Prices are delayed at least 15 minutes.
Who is Emergent BioSolutions's CEO?
Mr. Joseph C. Papa Jr., M.B.A., R.Ph. is the chief executive officer of Emergent BioSolutions Inc., which has about 900 employees.
What is the EBS 52-week high?
The 52-week high for EBS is $14.06 and the 52-week low is $4.36. The stock is currently 64.1% below its high.